Ocdjhular adverse reactions to tamoxifen - A review

Ophthalmic and Physiological Optics

Volumn 19, Issue SUPPL. 1, 1999, Pages

  Dulley, Polly ^a  

^a St Margaret's Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; DIFFERENTIAL DIAGNOSIS; EYE TOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ADULT; AGED; CHEMICALLY INDUCED DISORDER; CORNEA; DRUG EFFECT; EYE DISEASE; FEMALE; HUMAN; MIDDLE AGED; RETINA; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CORNEA; ESTROGEN ANTAGONISTS; EYE DISEASES; FEMALE; HUMANS; MIDDLE AGED; RETINA; TAMOXIFEN;

EID: 0033085385     PISSN: 02755408     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0275-5408(98)00084-2     Document Type: Article

References (49)

1. Anjna S., Shekar G. C., Rao D. R., Mohandas S. Superior ophthalmic vein thrombosis with tamoxifen. Can. J. Neurol. Sci. 20:(supp. 4):1993;197.
2. Ashford A. R., Donev I., Tiwari R. P., Garrett T. J. Reversible ocular toxicity related to tamoxifen therapy. Cancer. 61:1988;33-35.
3. Baltuch G., Shenouda G., Langleben A. High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilisation and tumour regression. Can. J. Neurol. Sci. 20:1993;168-170.
4. Beck M., Mills P. V. Ocular assessment of patients treated with tamoxifen. Cancer Treatment Rep. 63:1979;1833-1834.
5. Bentley C. R., Davies G., Aclimandos W. A. Tamoxifen retinopathy: a rare but serious complication. Brit. Med. J. 304:1992;495-496.
6. Berezovsky A., Middendorf R. C., Birch D. G. Electroretinographic findings in patients treated with tamoxifen. Invest. Ophthal. Vis. Sci. 37:1996;345.
7. Bernado G., Redaelli C., Plastina M., Bernado A., Strada M. R., Bottero G., Betta P. G. Long-term adjuvant therapy with tamoxifen. An evaluation of the ocular toxicity. Breast Cancer. Proc. Am. Soc. Clin. Oncol. 13:1994;106.
8. Carey R., Davis J., Lonning P. Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treat. Rep. 65:1981;793-795.
9. Chang T., Gonder J. R., Ventresca M. R. Low-dose tamoxifen retinopathy. Can. J. Ophthalmol. 27:1992;148-149.
10. Chern S., Danis R. P. Retinopathy associated with low-dose tamoxifen. Am. J. Ophthalmol. 116:1993;372-373.
11. Costa R. H. M., Dhooge M. R. P., Van Wind F., De Rouck A. F. Tamoxifen retinopathy: a case report. Bull. Soc. Belge Ophthalmol. 238:1990;161-168.
12. Crivellari D., Forner L., Galligiona E. Int. Conf. Adjuvant Therapy Primary Breast Cancer, St Gallen. 48:1988;abs. 1-32.
13. De Jong-Busnac M. Ophthalmological complications of low-dose tamoxifen in the treatment of breast carcinoma. Ned. Tijdschr. Geneeskd. 133:1989;514-516.
14. Delozier T., Julien J., Juret P. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomised trial. Breast Cancer Res. Treat. 7:1986;105-110.
15. Dickson R. B., Lippmann M. E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Rev. 8:1987;29-43.
16. Drenckhahn D., Lullmann-Rauch R. Drug-induced retinal lipidosis: differential susceptibilities of pigment epithelium and neuroretina toward several amphiphillic cationic drugs. Exp. Mol. Path. 28:1978;360-371.
17. Dulley P. A., Morgan M. W. E., Patel A., Fawcett I. Ocular toxicity from low dose tamoxifen. Eur. J. Surg. Oncol. 23:1997;abs. 99-36.
18. Edgar D. F., Gilmartin B. Ocular adverse reactions to systemic medication. Ophthal. Physiol. Opt. 17:(Suppl. 2):1997;S1-S8.
19. Garcia-Ruiz N., Sanchez M. C., Valenzuela P., Jimenez P., Rodriguez E., Cortes-Prieto J. Toxicidad ocular del tamoxifen: un caso de neuritis optica. Oncol. 17:1994;64-66.
20. Gerner W. E. Ocular toxicity of tamoxifen. Ann. Ophthalmol. 21:1989;420-423.
21. Griffiths M. F. P. Tamoxifen retinopathy at low dosage. Am. J. Ophthalmol. 104:1987;185-186.
22. Harper M. J. K., Walpole A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 13:1967;101-119.
23. Heier J. S., Dragoo R. A., Enzenauer R. W., Waterhouse W. J. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am. J. Ophthalmol. 117:1994;772-775.
24. Hobbs H. E., Eadie S. P., Somerville F. Ocular lesions after treatment with chloroquine. Brit. J. Ophthal. 45:1961;284-297.
25. Horowitz K. B., Koselli Y., McGuire W. L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinol. 103:1978;174-175.
26. Imperia P., Lazarus H., Lass J. Ocular complications of systemic chemotherapy. Surv. Ophthalmol. 34:1989;209-230.
27. Jordan, V. C. (1986). Estrogen/antiestrogen action and breast cancer therapy, Madison, University of Wisconsin.
28. Jordan V. C. Chemosuppression of breast cancer with tamoxifen - laboratory evidence and future clinical investigation. Cancer Invest. 6:1988;589-595.
29. Kaiser-Kupfer M. I., Lippmann M. E. Tamoxifen retinopathy. Cancer Treatment Reports. 62:1978;315-320.
30. Kaiser-Kupfer M. I., Kupfer C., Rodrigues M. M. Tamoxifen retinopathy: a clinicopathologic report. Ophthalmol. 88:1981;89-93.
31. Lauweryns B., Leys A., Missotten L. Tamoxifen-induced retinopathy. Tijdschrift voor Geneeskunde. 49:1993;185-186.
32. Lein E., Solheim E., Lea O. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49:1989;2175-2183.
33. Lein E., Wester K., Lonning P. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer. 63:1991;641-645.
34. Longstaff S., Sigurdsson H., O'Keefe M., Ogsten S., Preece P. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur. J. Cancer Clin. Oncol. 25:1989;1805-1808.
35. Love R. R. Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J. Clinical Oncology. 7:1989;803-815.
36. Lullman H., Lullman-Rauch R. Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses. Toxicol. Appl. Pharmacol. 61:1981;138-146.
37. McKeown C. A., Swartz M., Blom J., Maggiano J. M. Tamoxifen retinopathy. Brit. J. Ophthal. 65:1981;177-179.
38. Mulholland B., Flaxel C. J., Hayes B., Gregor Z. J. Ocular penetration of tamoxifen in patients on systemic treatment for breast cancer. Invest. Ophthalmol. Vis. Sci. 36:1995;132.
39. Onofrey B. Maculopathy secondary to tamoxifen use. Chilton's review of Optometry. 43:1993.
40. Pavlidis N. A., Petris C., Briassoulis E., Klouvas G., Psilas C., Rempapis J., Petroutsos G. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer. 69:1992;2961-2964.
41. Pugesgaard T., Von Eyben F. E. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer. 58:1986;383-386.
42. Reuther U., Nunnensiek C., Sessler R., Stilz S., Ulshoefer T., Mueller H. A. G., Bader H., Bokemeyer C., Toomes H., Jipp P. Efficacy of antiestrogen treatment in a benign metastasizing leiomyoma with paraneoplastic estradiol production. Oncology Rep. 3:1996;293-299.
43. Ribeiro G., Swindell R. The Christy hospital tamoxifen adjuvant trial for operable breast carcinoma - 7 year results. Eur. J. Cancer Clin. Oncol. 21:1985;897-900.
44. Schlich B., Heidrich H., Keuch R., Bleckmann H. Occlusion of the finger arteries and thrombotic retinal angiopathy during adjuvant treatment of breast cancer with tamoxifen. Deutsche Medizinische Wochenschrift. 122:1997;783-786.
45. Smith L., Clarke M. Ophthalmic manifestations of metastatic carcinoma of the breast. J. R. Soc. Med. 85:1992;363.
46. Tang R., Shields J., Schiffman J., Li H., Locher D., Hampton J., Prager T., Pardo G. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 11:1997;295-297.
47. Vinding T., Nielsen N. V. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthal. 61:1982;45-50.
48. Vize C. Case report - tamoxifen retinopathy. Eyenews. 4:1997;26.
49. Watkins S. M. The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study. Br. J. Cancer. 57:1988;320-321.